Shots:

• AzurRx to acquire First Wave Bio for $229M in cash & stock including development- regulatory & sales milestones. The transaction is anticipated to close imminently
• The acquisition will boost AzurRx’s GI pipeline including three new clinical IBD indications for UPS- UC & CD. In Jan’21- AzurRx in-licensed an exclusive global right to develop two niclosamide therapeutic indications for COVID-19-related GI infections & ICI-AC in cancer patients
• AzurRx will change its corporate name to First Wave BioPharma under the new ticker symbol “FWBI”. The acquisition allows AzurRx to retain all rights to First Wave Bio’s niclosamide formulations to treat multiple GI condition

  | Ref: Globe Newswire | Image: AzurRx